Trials / Completed
CompletedNCT00002188
A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma
Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (planned)
- Sponsor
- Anderson Clinical Research · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).
Detailed description
Patients receive open-label ALRT1057 for 16 weeks, as tolerated. In the absence of unacceptable toxicity, patients may continue treatment indefinitely provided they continue to benefit from therapy and the study remains open and active. Thirteen patients are treated initially. If at least one response is observed in these patients, up to 14 additional patients will be evaluated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alitretinoin |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Source: ClinicalTrials.gov record NCT00002188. Inclusion in this directory is not an endorsement.